Abbott's Tendyne transcatheter mitral valve replacement (TMVR) system was approved by the FDA and indicated for those with ...

The approval is tightly defined: the system will be for patients ineligible for surgery and with anatomy unfavorable for TEER ...

The FDA approved Abbott's Tendyne minimally invasive heart replacement for mitral valve disease that could disqualify ...

Abbott Laboratories (NYSE:ABT) has received FDA approval today for its Tendyne™ transcatheter mitral valve replacement (TMVR) ...

ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.

Abbott (NYSE: ABT) announced today that it received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR ...

The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne ...

The Tendyne system is designed for those who are considered high-risk for traditional open-heart surgery and for whom mitral valve repair with Abbott’s MitraClip is not a viable option.

US FDA approves Abbott’s Tendyne, first-of-its-kind device to replace the mitral valve without open-heart surgery: Abbott Park, Illinois Thursday, May 29, 2025, 16:00 Hrs [IST] ...